vs

Side-by-side financial comparison of Apyx Medical Corp (APYX) and PRO DEX INC (PDEX). Click either name above to swap in a different company.

Apyx Medical Corp is the larger business by last-quarter revenue ($19.2M vs $18.7M, roughly 1.0× PRO DEX INC). PRO DEX INC runs the higher net margin — 11.7% vs -6.8%, a 18.5% gap on every dollar of revenue. On growth, Apyx Medical Corp posted the faster year-over-year revenue change (34.7% vs 11.1%). PRO DEX INC produced more free cash flow last quarter ($3.5M vs $-2.8M). Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs 14.3%).

Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.

Pro Dex Inc is a precision manufacturing enterprise that produces custom machined components, subassemblies and finished products primarily for medical device original equipment manufacturers, as well as clients in the aerospace and industrial sectors, with its core operating market covering North America.

APYX vs PDEX — Head-to-Head

Bigger by revenue
APYX
APYX
1.0× larger
APYX
$19.2M
$18.7M
PDEX
Growing faster (revenue YoY)
APYX
APYX
+23.6% gap
APYX
34.7%
11.1%
PDEX
Higher net margin
PDEX
PDEX
18.5% more per $
PDEX
11.7%
-6.8%
APYX
More free cash flow
PDEX
PDEX
$6.3M more FCF
PDEX
$3.5M
$-2.8M
APYX
Faster 2-yr revenue CAGR
APYX
APYX
Annualised
APYX
36.8%
14.3%
PDEX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
APYX
APYX
PDEX
PDEX
Revenue
$19.2M
$18.7M
Net Profit
$-1.3M
$2.2M
Gross Margin
62.6%
30.8%
Operating Margin
0.1%
17.5%
Net Margin
-6.8%
11.7%
Revenue YoY
34.7%
11.1%
Net Profit YoY
71.9%
7.2%
EPS (diluted)
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APYX
APYX
PDEX
PDEX
Q4 25
$19.2M
$18.7M
Q3 25
$12.9M
$18.5M
Q2 25
$11.4M
$17.5M
Q1 25
$9.4M
$17.4M
Q4 24
$14.2M
$16.8M
Q3 24
$11.5M
$14.9M
Q2 24
$12.1M
$15.0M
Q1 24
$10.2M
$14.3M
Net Profit
APYX
APYX
PDEX
PDEX
Q4 25
$-1.3M
$2.2M
Q3 25
$-2.0M
$4.7M
Q2 25
$-3.8M
$1.2M
Q1 25
$-4.2M
$3.3M
Q4 24
$-4.6M
$2.0M
Q3 24
$-4.7M
$2.5M
Q2 24
$-6.6M
$1.6M
Q1 24
$-7.6M
$655.0K
Gross Margin
APYX
APYX
PDEX
PDEX
Q4 25
62.6%
30.8%
Q3 25
64.4%
29.0%
Q2 25
62.3%
19.9%
Q1 25
60.1%
33.3%
Q4 24
63.0%
30.2%
Q3 24
60.5%
34.6%
Q2 24
61.7%
27.2%
Q1 24
58.1%
28.0%
Operating Margin
APYX
APYX
PDEX
PDEX
Q4 25
0.1%
17.5%
Q3 25
-6.5%
16.8%
Q2 25
-22.6%
7.7%
Q1 25
-32.4%
20.9%
Q4 24
-21.4%
16.0%
Q3 24
-31.6%
20.2%
Q2 24
-45.7%
15.6%
Q1 24
-64.6%
15.5%
Net Margin
APYX
APYX
PDEX
PDEX
Q4 25
-6.8%
11.7%
Q3 25
-15.4%
25.3%
Q2 25
-33.2%
6.8%
Q1 25
-44.0%
18.8%
Q4 24
-32.5%
12.1%
Q3 24
-40.9%
16.6%
Q2 24
-54.0%
10.6%
Q1 24
-74.0%
4.6%
EPS (diluted)
APYX
APYX
PDEX
PDEX
Q4 25
$0.66
Q3 25
$1.40
Q2 25
$0.33
Q1 25
$0.98
Q4 24
$0.61
Q3 24
$0.75
Q2 24
$-0.19
$0.44
Q1 24
$-0.22
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APYX
APYX
PDEX
PDEX
Cash + ST InvestmentsLiquidity on hand
$31.7M
$6.1M
Total DebtLower is stronger
$37.5M
Stockholders' EquityBook value
$14.5M
$41.6M
Total Assets
$66.8M
$62.3M
Debt / EquityLower = less leverage
2.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APYX
APYX
PDEX
PDEX
Q4 25
$31.7M
$6.1M
Q3 25
$25.1M
$10.1M
Q2 25
$29.3M
$6.8M
Q1 25
$31.0M
$5.5M
Q4 24
$31.7M
$4.7M
Q3 24
$28.0M
$7.8M
Q2 24
$32.7M
$6.8M
Q1 24
$37.3M
$7.8M
Total Debt
APYX
APYX
PDEX
PDEX
Q4 25
$37.5M
Q3 25
$37.5M
Q2 25
$37.5M
$15.4M
Q1 25
$37.5M
Q4 24
$37.5M
Q3 24
$37.5M
Q2 24
$12.0M
Q1 24
Stockholders' Equity
APYX
APYX
PDEX
PDEX
Q4 25
$14.5M
$41.6M
Q3 25
$5.8M
$41.5M
Q2 25
$7.3M
$36.6M
Q1 25
$10.5M
$35.3M
Q4 24
$14.2M
$31.8M
Q3 24
$11.0M
$30.9M
Q2 24
$14.7M
$30.9M
Q1 24
$20.3M
$30.9M
Total Assets
APYX
APYX
PDEX
PDEX
Q4 25
$66.8M
$62.3M
Q3 25
$57.4M
$64.3M
Q2 25
$58.2M
$61.2M
Q1 25
$60.2M
$64.3M
Q4 24
$64.8M
$60.4M
Q3 24
$60.7M
$54.3M
Q2 24
$65.4M
$52.5M
Q1 24
$70.7M
$50.5M
Debt / Equity
APYX
APYX
PDEX
PDEX
Q4 25
2.58×
Q3 25
6.41×
Q2 25
5.17×
0.42×
Q1 25
3.57×
Q4 24
2.64×
Q3 24
3.40×
Q2 24
0.39×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APYX
APYX
PDEX
PDEX
Operating Cash FlowLast quarter
$-2.5M
$3.6M
Free Cash FlowOCF − Capex
$-2.8M
$3.5M
FCF MarginFCF / Revenue
-14.6%
18.8%
Capex IntensityCapex / Revenue
1.4%
0.4%
Cash ConversionOCF / Net Profit
1.63×
TTM Free Cash FlowTrailing 4 quarters
$-9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APYX
APYX
PDEX
PDEX
Q4 25
$-2.5M
$3.6M
Q3 25
$-3.5M
$2.3M
Q2 25
$-1.2M
$-173.0K
Q1 25
$-702.0K
$754.0K
Q4 24
$-2.9M
$-4.2M
Q3 24
$-4.4M
$1.9M
Q2 24
$-4.3M
$1.0M
Q1 24
$-6.3M
$4.1M
Free Cash Flow
APYX
APYX
PDEX
PDEX
Q4 25
$-2.8M
$3.5M
Q3 25
$-4.1M
$2.2M
Q2 25
$-1.5M
Q1 25
$-757.0K
$574.0K
Q4 24
$-3.2M
$-4.7M
Q3 24
$-4.6M
$1.5M
Q2 24
$-4.6M
Q1 24
$-6.4M
$4.0M
FCF Margin
APYX
APYX
PDEX
PDEX
Q4 25
-14.6%
18.8%
Q3 25
-31.5%
11.9%
Q2 25
-13.2%
Q1 25
-8.0%
3.3%
Q4 24
-22.4%
-27.9%
Q3 24
-40.0%
9.8%
Q2 24
-38.0%
Q1 24
-62.2%
27.7%
Capex Intensity
APYX
APYX
PDEX
PDEX
Q4 25
1.4%
0.4%
Q3 25
4.0%
0.5%
Q2 25
2.3%
Q1 25
0.6%
1.0%
Q4 24
1.7%
3.2%
Q3 24
1.3%
2.9%
Q2 24
2.4%
Q1 24
0.3%
0.8%
Cash Conversion
APYX
APYX
PDEX
PDEX
Q4 25
1.63×
Q3 25
0.49×
Q2 25
-0.14×
Q1 25
0.23×
Q4 24
-2.03×
Q3 24
0.77×
Q2 24
0.66×
Q1 24
6.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons